Hypertension is among the most prevalent and most consequential modifiable cardiovascular risk factors, and its effects on the brain are substantial. Decades of accumulated evidence — most prominently the SPRINT-MIND trial — have demonstrated that intensive blood pressure control reduces incidence of mild cognitive impairment and slows the progression of vascular cognitive impairment. The Lancet Commission framework lists hypertension as a modifiable risk factor with meaningful population-attributable fraction. For longevity psychiatry, blood pressure management is brain medicine first and cardiovascular medicine second.
The mechanism of hypertensive brain damage is multimodal. Sustained elevated pressure damages small vessels through arteriolosclerosis and lipohyalinosis, producing the small vessel disease covered in L7.1. White matter integrity declines over time. Cerebral blood flow regulation becomes impaired. The cumulative effect over decades is the substrate of vascular cognitive impairment and, in many patients, mixed pathology contributing to apparent Alzheimer's-type dementia. The intervention point is decades upstream of clinical decline — controlling blood pressure in the 40s and 50s is what protects cognition in the 70s and 80s.
The SPRINT-MIND target is under 130 systolic, derived from a large randomized trial that demonstrated intensive control (target under 120 systolic, achieved approximately 121 systolic in the trial arm) reduced incidence of MCI compared to standard control (target under 140, achieved approximately 134). The 130 systolic target represents a pragmatic threshold that captures most of the cognitive benefit while reducing risk of hypotension-related side effects. Some longevity-medicine practice targets are even tighter for selected patients. The clinical principle is that the older general-population target of 140 systolic is insufficient for cognitive protection in most patients.
Pharmacological choice matters somewhat. ACE inhibitors and ARBs have cerebrovascular evidence supporting their use; angiotensin-receptor blockers in particular have some data suggesting cognitive benefit beyond pressure lowering alone. Dihydropyridine calcium channel blockers (amlodipine, nifedipine) are effective and have favorable cerebrovascular profiles. Thiazide diuretics remain useful, particularly in older adults and patients with isolated systolic hypertension. Beta blockers are less preferred as first-line for blood pressure when cognitive protection is a priority, though they have other clinical roles. The clinical move is to choose agents with cerebrovascular evidence and to use combination therapy aggressively when single agents are insufficient.
The practical challenges of intensive blood pressure control include adherence (multiple medications, side effects, the psychological burden of chronic preventive treatment) and the realistic limit of how tightly some patients can be controlled. Patients with isolated systolic hypertension and significant arterial stiffness may not tolerate diastolic pressures that drop too low. Patients with frailty in late life may not benefit from intensive control to the same degree as patients in the acceleration window. The clinical discipline is to apply the target aggressively in patients who will benefit while recognizing where the trade-offs change in older or frailer populations.
Home blood pressure monitoring and ambulatory measurement often reveal patterns that office measurements miss — white coat effects, masked hypertension, nocturnal non-dipping (the failure to drop blood pressure during sleep, which is its own cerebrovascular risk factor). The longevity-psychiatry approach includes home or ambulatory monitoring for any patient where the picture is unclear, and explicit attention to the nocturnal pattern as part of cerebrovascular risk assessment.